This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
Align Technology (ALGN) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from robust Invisalign aligners and iTero scanners shipment volume in Q1.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on the back of product launches and impressive geographical growth.
DaVita (DVA) Partners With Fresenius, Boost Home Dialysis Care
by Zacks Equity Research
DaVita's (DVA) recent collaboration will help patients benefit from the portability, dependability and flexibility of NxStage home machines, designed to be easy to use.
Baxter (BAX) Receives FDA Nod for AK 98 Hemodialysis Machine
by Zacks Equity Research
Baxter (BAX) gets FDA approval for its AK 98 Hemodialysis machine that offers a compact, portable and easy-to-use system for dialysis providers.
Why Is Baxter (BAX) Up 1.1% Since Last Earnings Report?
by Zacks Equity Research
Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Baxter (BAX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results reflect robust performance across five of its business units.
Baxter International (BAX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 5.26% and 0.83%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter performance is likely to reflect growth in its Acute Therapies business.
Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter (BAX) Inks Sterile Manufacturing Agreement With Novavax
by Zacks Equity Research
Baxter's (BAX) BioPharma Solutions business inks deal to advance commercial-scale production and increase access for the COVID-19 vaccine in the U.K. and European markets.
Baxter's (BAX) Vital Edge Program Aids Patient Blood Management
by Zacks Equity Research
Baxter's (BAX) Vital Edge program enables AdventHealth Tampa to achieve cost savings.
Baxter (BAX) Announces Site Expansion to Improve Patient Care
by Zacks Equity Research
Baxter's (BAX) latest site expansion is aimed at better serving its client and patient pool along with employment creation.
Baxter (BAX) Gets FDA Nod for Homechoice Claria APD System
by Zacks Equity Research
Baxter's (BAX) Homechoice Claria combines a simple user interface with the benefits of Sharesource.
Zacks Industry Outlook Highlights: Abbott Laboratories, Baxter International, ResMed and Intuitive Surgical
by Zacks Equity Research
Zacks Industry Outlook Highlights: Abbott Laboratories, Baxter International, ResMed and Intuitive Surgical
3 Stocks to Capitalize on Promising Medical Products Industry
by Trina Mukherjee
Despite the challenges triggered by the COVID-19 pandemic, higher demand for IVD products, digital influence and AI & Robotics are likely to lend support to the Zacks Medical - Products industry. ABT, BAX and RMD are well positioned to gain from the prospects.
Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) third-quarter results reflect strong performance across six of its business units.
Medical Products' Oct 29 Earnings Roster: SYK, BAX & More
by Trina Mukherjee
Medical Product companies have shown strength in the third quarter on the back of huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.
Baxter (BAX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) third-quarter performance is likely to reflect growth in its Acute Therapies business.
Baxter Supports Findings of Ongoing COVID-19 Nutrition Study
by Zacks Equity Research
The study, supported by Baxter (BAX) through an investigator-initiated grant, is the first analysis of longitudinal REE in critically ill, mechanically-ventilated COVID-19 patients.
Baxter's Clinimix and Clinimix E Injections Receive FDA Nod
by Zacks Equity Research
Baxter's (BAX) Clinimix and Clinimix E with Higher Protein Injection received FDA approval, which will help clinicians to improve care for critically ill patients.
Nevro Bolsters Growth Prospects With New Manufacturing Plan
by Zacks Equity Research
Nevro (NVRO) commences plan for manufacturing operations in Costa Rica, thereby expanding its geographic footprint and boosting growth prospects.
Baxter (BAX) Attains FDA De Novo Authorization for Theranova
by Zacks Equity Research
Baxter's (BAX) expanded HDx therapy delivered by Theranova becomes accessible for patients with kidney failure in the United States.
How Has BAX Performed 30 Days Post Earnings
by Zacks Equity Research
Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Baxter (BAX) Receives EUA for Regiocit Replacement Solution
by Zacks Equity Research
Baxter (BAX) receives EUA from the FDA for Regiocit, which is the only authorized citrate-based replacement solution for use in CRRT during the COVID-19 pandemic.
Baxter (BAX) Earnings and Revenues Miss Estimates in Q2
by Zacks Equity Research
Baxter's (BAX) second-quarter earnings reflect weak performance across Medication Delivery, Pharmaceutical and Advanced Surgery business units and contraction in margins.